The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

Gosling, Roly D., Uiso, Leonard O., Sam, Noel E., Bongard, Emily ORCID: https://orcid.org/0000-0001-5957-6280, Kanduma, Esther G., Nyindo, Mramba, Morris, Richard W. and Gillespie, Stephen H. 2003. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 168 (11) , pp. 1342-1345. 10.1164/rccm.200305-682OC

Full text not available from this repository.

Abstract

Patients in whom acid-fast bacilli smear-positive pulmonary tuberculosis was newly diagnosed were randomized to receive 400 mg moxifloxacin, 300 mg isonaizid, or 600 mg rifampin daily for 5 days. Sixteen-hour overnight sputa collections were made for the 2 days before and for 5 days of monotherapy. Bactericidal activity was estimated by the time taken to kill 50% of viable bacilli (vt50) and the fall in sputum viable count during the first 2 days designated as the early bactericidal activity (EBA). The mean vt50 of moxifloxacin was 0.88 days (95% confidence interval [CI], 0.43–1.33 days) and the mean EBA was 0.53 (95% CI 0.28–0.79). For the isoniazid group, the mean vt50 was 0.46 days (95% CI, 0.31–0.61 days) and the mean EBA was 0.77 (95% CI, 0.54–1.00). For rifampin, the mean vt50 was 0.71 days (95% CI, 0.48–0.95 days) and the mean EBA was 0.28 (95% CI, 0.15–0.41). Using the EBA method, isoniazid was significantly more active than rifampin (p < 0.01) but not moxifloxacin. Using the vt50 method, isoniazid was more active than both rifampin and moxifloxacin (p = 0.03). Moxifloxacin has an activity similar to rifampin in human subjects with pulmonary tuberculosis, suggesting that it should undergo further assessment as part of a short course regimen for the treatment of drug-susceptible tuberculosis.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	Q Science > QR Microbiology R Medicine > R Medicine (General)
Uncontrolled Keywords:	clinical trials; Africa; tuberculosis; quinolone
Publisher:	American Thoracic Society
ISSN:	1073-449X
Last Modified:	25 Oct 2022 08:43
URI:	https://orca.cardiff.ac.uk/id/eprint/54067

Citation Data

Cited 153 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item